<DOC>
	<DOCNO>NCT00454168</DOCNO>
	<brief_summary>RATIONALE : Vaccines make peptide may help body build effective immune response kill cancer cell . Colony-stimulating factor , GM-CSF , increase number white blood cell platelets find bone marrow peripheral blood . Giving vaccine therapy together GM-CSF may effective treatment acute myeloid leukemia . It yet know whether give vaccine therapy together GM-CSF effective give placebo together GM-CSF treat acute myeloid leukemia . PURPOSE : This randomized phase III trial study vaccine therapy GM-CSF see well work compare placebo GM-CSF treating patient acute myeloid leukemia remission .</brief_summary>
	<brief_title>Vaccine Therapy GM-CSF Treating Patients With Acute Myeloid Leukemia Remission</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare improvement overall survival patient acute myeloid leukemia treat PR1 leukemia peptide vaccine sargramostim ( GM-CSF ) v placebo vaccine GM-CSF . Secondary - Compare improvement relapse-free survival patient treat regimen . - Compare remission duration patient treat regimen . - Compare immune response , measure PR1-HLA-A2 tetramer assay , patient treat regimen . OUTLINE : This randomize , placebo-controlled , multicenter study . Patients stratify accord age complete remission ( CR ) ( ≥ 18 year age second CR v ≥ 55 year age first CR ) , type acute myeloid leukemia ( de novo v secondary ) , cytogenetics ( unfavorable v favorable intermediate ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive PR1 leukemia peptide vaccine sargramostim ( GM-CSF ) subcutaneously ( SC ) . - Arm II : Patients receive placebo vaccine GM-CSF SC . PROJECTED ACCRUAL : A total 244 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia ( AML ) , define presence &gt; 20 % blast marrow blood , include follow subtypes : De novo AML , define AML clinical history prior myelodysplastic syndrome ( MDS ) myeloproliferative disorder ( MPD ) exposure potentially leukemogenic therapy agent Secondary AML , define follow : AML secondary prior exist MDS MPD development AML secondary proven leukemogenic exposure History fatigue , bleeding , recurrent infection precede diagnosis AML ≥ 1 month confirmation exist peripheral blood film demonstrate morphologic dysplasia In first complete remission ( CR ) ( patient ≥ 55 year age ) OR second CR ( patient ≥ 18 year age ) within past month FAB stag M0M2 M4M7 allow first CR No acute promyelocytic leukemia first CR FAB stag M0M7 allow second CR Marrow blast count &lt; 5 % ( ≤ 200 nucleate cell count ) No blast blood HLAA2 positive 1 allele No extramedullary disease No Auer rods No active meningeal CNS leukemia PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy must severely limited disease Absolute neutrophil count &gt; 1,000/mm^3 Platelet count &gt; 100,000/mm^3 Bilirubin &lt; 2 mg/mL ALT &lt; 2 time upper limit normal Creatinine ≤ 1.6 mg/mL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Antineutrophil cytoplasmic antibody negative No serious medical condition , laboratory abnormality , psychiatric illness would preclude study compliance increase risk patient No malignancy within past 5 year except basal cell squamous cell carcinoma carcinoma situ cervix breast No known allergy incomplete Freund 's adjuvant No hypercalcemia No progressive viral bacterial infection Must afebrile 7 day without antibiotic No symptomatic cardiac disease LVEF ≥ 40 % No symptomatic pulmonary disease FEV_1 , FVC , DLCO ≥ 50 % predicate ( without bronchodilator ) No history HIV positivity AIDS No know hypersensitivity sargramostim ( GMCSF ) , yeastderived product , component product No history Wegener 's granulomatosis vasculitis PRIOR CONCURRENT THERAPY : Recovered prior surgery and/or radiotherapy No prior allogeneic syngeneic stem cell transplantation No prior solid organ transplantation No prior vaccine therapy AML More 28 day since prior chronic use ( &gt; 2 week ) corticosteroid &gt; 10 mg/day ( prednisone [ equivalent ] ) Concurrent topical inhale corticosteroid allow More 3 month since prior experimental therapy , cyclosporine , tacrolimus No concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
</DOC>